136. Vaccine economics, and why we need trade to end the pandemic

Episode Summary

Executive Summary: The episode examines how COVID-19 vaccines should be financed, produced, and distributed fairly once available, focusing on Gavi’s COVAX facility and CEPI’s portfolio approach. The hosts and Ngozi Okonjo-Iweala argue that rich-country vaccine nationalism could leave poorer countries behind, worsen global inequity, and ultimately fail because supply chains and inputs are internationally interdependent.

Main Topics: COVAX and global vaccine allocation (Priority: 5/5): The episode explains COVAX as a mechanism to pool demand and distribute vaccines more equitably across rich and poor countries, aiming to avoid a race in which wealthier states monopolize supply. Gavi’s mission and track record (Priority: 5/5): Ngozi Okonjo-Iweala describes Gavi as a response to market failure in global immunization and highlights its success in vaccinating children and lowering vaccine prices. Manufacturing constraints and vaccine complexity (Priority: 4/5): The hosts stress that vaccines are technically difficult to produce, require certification and specialized facilities, and cannot be freely manufactured everywhere, limiting the effectiveness of simple patent-sharing arguments. Financing and advance market commitments (Priority: 5/5): The episode details the high upfront costs and risks of vaccine R&D and manufacturing, and how Gavi’s advanced market commitment is intended to guarantee demand and incentivize production. Vaccine nationalism and export restrictions (Priority: 5/5): A major concern is that rich countries may hoard doses or impose export restrictions, undermining global sharing and causing countries to distrust cooperative arrangements like COVAX. CEPI’s portfolio strategy (Priority: 4/5): CEPI’s role is to fund multiple vaccine candidates and encourage early sharing of successful candidates, reducing risk by not relying on a single shot at success. WTO, trade rules, and future governance (Priority: 3/5): The conversation closes by asking how the WTO can help set rules for life-saving goods, intellectual property, and licensing during pandemics, and whether the WTO itself needs reform.

Key Arguments: Vaccines should be treated as a global public-good problem, not a purely national one, because no country is safe until all countries can access protection. Gavi was created to fix market failures that left developing-country children unvaccinated long after vaccines were available in rich countries. COVAX can improve outcomes by pooling demand, securing production volumes, lowering prices, and ensuring at least partial access for every participating country. The scientific and manufacturing complexity of vaccines means they cannot be instantly or universally produced by many local firms, even if intellectual property barriers were removed. Advance market commitments can reduce uncertainty for manufacturers and make large-scale production financially viable before the vaccine exists. Vaccine nationalism is self-defeating because export bans, retaliation, and chokepoints in inputs like adjuvants can disrupt production for everyone. Governments may resist sharing because voters reward national first access, but public opinion may be shifting as people recognize the need to think beyond borders. The WTO has an opportunity to strengthen or update rules for trade, licensing, and access to life-saving medical goods during pandemics.

Data Points: Vaccines in development: 165 - Number of coronavirus vaccines in development as of early August. Vaccines in clinical trials: 26 - Subset of vaccines already in clinical trials. Vaccines in phase 3 trials: 6 - Late-stage candidates nearing potential distribution. Children vaccinated by Gavi: 760 million - Total children Gavi has helped vaccinate since its founding. Lives saved by Gavi: 30 million - Estimated lives saved through Gavi-supported immunization. Gavi goal for 2021-2025: 300 million children vaccinated - Future target for Gavi over the next five years. Gavi goal for 2021-2025: 8 million lives saved - Projected lives saved by Gavi in the 2021-2025 period. Indicative vaccine price in rich countries: $100 per dose - Illustrative cost comparison used to show high-income-country pricing. Indicative vaccine price via Gavi: $25, $3.50, or $2.50 per dose - Examples of lower procurement prices depending on the vaccine. Countries in COVAX needing support: 92 developing countries - Low- and lower-middle-income countries requiring financial assistance. Potential vaccine manufacturing capacity by end-2021: 2 to 4 billion doses - CEPI survey estimate cited during discussion. World population: around 8 billion - Used to illustrate the global shortfall in vaccine supply. Target coverage under COVAX: about 20% of each participating country's population - Approximate coverage intended by the initial COVAX allocation model.

Pivotal Quotes: "The fundamental problem we're trying to solve is to make sure that we have an inclusive approach to getting vaccines to everyone." — Ngozi Okonjo-Iweala: Explaining Gavi/COVAX’s mission to avoid rich-country capture of vaccine supply. "If the vaccines only go to the rich countries, it's the equivalent of being on an airplane and having those masks fall down to give you oxygen... but having them only fall down if you're a person sitting in first class." — Samaya Keynes / Chad Bown: A metaphor for unequal vaccine access and global inequity. "This is actually a time for the WTO to shine." — Ngozi Okonjo-Iweala: Discussing how the WTO could help set pandemic-era trade and intellectual-property rules.

Implications: The episode argues that vaccine access will depend on coordinated financing, manufacturing, and trade rules. Without cooperation, richer countries may hoard doses and trigger retaliation; with it, the world can speed production and save more lives.